BTC Benitec Biopharma is sitting now at a key support from which we can expect a bounce.
We know that earlier this year they had a 7.5mil offering price to the public of $4.25 per share and that Morgan Stanley has a 5.2% stake in the genetic drug company.
Benitec's "proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration.